Loading...
Market
What will be Eli Lilly's Zepbound market share in the weight-loss drug market by the end of Q1 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market research reports from firms like Gartner or IDC
Story
Eli Lilly Launches 50% Discounted Zepbound Vials in 2.5 mg and 5 mg Doses
Aug 27, 2024, 11:29 AM
Eli Lilly has announced the release of single-dose vials of its weight-loss drug Zepbound (tirzepatide) in the United States, aimed at expanding access and addressing supply constraints. The new vials are available in 2.5 mg and 5 mg doses, priced at $399 and $549 for a four-week supply, respectively. This represents a 50% discount compared to the previous cost of injection pens. The move is intended to provide more affordable options for patients without insurance coverage and is distributed through Lilly's direct-to-consumer platform, LillyDirect. This initiative is also seen as a response to pharmacies compounding the drug and aims to challenge telehealth companies offering compounded versions. The announcement has impacted the stock of companies like Hims & Hers Health, which saw a decline following the news.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%